R&D Clinical Trials Round-Up – Jan to Feb 2026 Read how Jan-Feb '26 offered a revealing cross-section of how R&D is evolving across therapy areas.
Oncology Advancing radiopharmaceutical development: Preclinical preci... Radiopharmaceutical development must move beyond fixed paradigms toward patient-specific, data-driven optimisation.
R&D What’s holding back precision medicine outside oncology? Precision medicine is finding success in cancer care, but not much elsewhere. The reasons why are often more economic than scientific.
R&D Precision medicine - closing the loop: What happens after th... We often talk about diagnostics as the gateway to precision medicine. But what happens before and after the test?
R&D Built for one: The case for custom formulation in the era of... The precision medicine market is projected to exceed $175 billion by 2030, reflecting continued growth and interest in innovative approaches that tailor therapeutics that accounts for diffe
Oncology AACR 2025: New modalities and remaining challenges Explore the latest advancements and challenges in ADC therapy at AACR 2025: New modalities and remaining challenges
News CHMP backs Novo's haemophilia A drug Frehemgo Novo has moved a step closer to EU approval of its long-acting haemophilia A therapy, Frehemgo, which could be a future blockbuster.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
